Neural Therapeutics (XCNQ:NURL) Total Assets: C$1.64 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Total Assets?

Neural Therapeutics XCNQ:NURL Total Assets is C$1.64 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Total Assets for the quarter that ended in Jan. 2026 was C$1.64 Mil.

During the past 12 months, Neural Therapeutics's average Total Assets Growth Rate was -6.90% per year. During the past 3 years, the average Total Assets Growth Rate was -31.20% per year. During the past 5 years, the average Total Assets Growth Rate was -45.60% per year.

During the past 6 years, Neural Therapeutics's highest 3-Year average Total Assets Growth Rate was -26.90%. The lowest was -71.30%. And the median was -31.20%.

Total Assets is connected with ROA %. Neural Therapeutics's annualized ROA % for the quarter that ended in Jan. 2026 was -86.34%. Total Assets is also linked to Revenue through Asset Turnover. Neural Therapeutics's Asset Turnover for the quarter that ended in Jan. 2026 was 0.00.

Neural Therapeutics  (XCNQ:NURL) Total Assets Explanation

Total Assets is connected with ROA %.

Neural Therapeutics's annualized ROA % for the quarter that ended in Jan. 2026 is

ROA %=Net Income (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=-1.564/( (1.982+1.641)/ 2 )
=-1.564/1.8115
=-86.34 %

Note: The Net Income data used here is four times the quarterly (Jan. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Neural Therapeutics's Asset Turnover for the quarter that ended in Jan. 2026 is

Asset Turnover
=Revenue (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=0/( (1.982+1.641)/ 2 )
=0/1.8115
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Neural Therapeutics Total Assets Related Terms

Neural Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Total Assets Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Assets
Get a 7-Day Free Trial 1.23 0.46 0.35 0.10 0.19

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.32 0.19 1.98 1.64

Neural Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Neural Therapeutics's Total Assets for the fiscal year that ended in Jul. 2025 is calculated as

Total Assets=Total Equity (A: Jul. 2025 )+Total Liabilities (A: Jul. 2025 )
=-0.728+0.92
=0.19

Neural Therapeutics's Total Assets for the quarter that ended in Jan. 2026 is calculated as

Total Assets=Total Equity (Q: Jan. 2026 )+Total Liabilities (Q: Jan. 2026 )
=0.653+0.988
=1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of C$1.64 Mil mean?
Neural Therapeutics (XCNQ:NURL) has a Total Assets of C$1.64 Mil as of Jan. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Total Assets too high?
Neural Therapeutics' current Total Assets is C$1.64 Mil.
How does Neural Therapeutics' Total Assets compare to VRTX and REGN?
Neural Therapeutics' Total Assets of C$1.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Total Assets is C$1.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (XCNQ:NURL) has a current Total Assets of C$1.64 Mil. The current Total Assets is C$1.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Neural Therapeutics (XCNQ:NURL), the current Total Assets is C$1.64 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:Germany
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.